NEW YORK CITY, NY / ACCESSWIRE / December 4, 2018 / Dwight Egan, CEO of Co-Diagnostics Inc, (CODX) a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, will be discussing upcoming sales expectations in a virtual investor conference today December 4, 2018 at 4:00 pm ET. The conference is also expected to include a review of milestones reached so far in 2018.
Mr. Egan sat down for an interview with the Wall Street Club in November to discuss certain Company advancements, including the following topics:
- The importance of the LGC, Biosearch license agreement for the Company's technology, and its near- and long-term impact on the Company;
- Momentum being built by recent advancements in the Company's patented intellectual property and regulatory clearance, the expectation of increased sales as a result and entry into the new verticals of liquid biopsy and agriculture; and
- The importance of the Company's new website in telling their story and showcasing the expanded applications of the Company's patented technology in multiplexing, SNP detection, next gen sequencing, and more.
Video and transcript of the interview can be found here: WallStreetClub.com
Participants in the investor conference today at 4.00 pm ET can hear further discussion of these topics and more, and submit questions for a chance to hear Mr. Egan address them directly. Access is available through the Company's Events and Presentations page.
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in liquid biopsy and SNP detection, (iv) use of the Company's liquid biopsy tests by laboratories, (v) capital resources and runway needed to advance the Company's products and markets, (vi) increased sales in the near-term, (vii) flexibility in managing the Company's balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
About BDA International, Inc.:
BDA International is an independent global Investor Relations firm offering a wide range of IR-related analysis, research and advisory services. In particular, we provide strategic action plans, and investor/market perception studies to help entities improve communication with customers and investors and increase their visibility. BDA International accepts sole responsibility for the content and distribution of the foregoing release.
Investor Relations Contact:
SOURCE: Co-Diagnostics Inc.